Latest news with #LisaPham
Bloomberg
2 days ago
- Business
- Bloomberg
Short Sellers Raised Bets Against Worldline Before Fraud Reports
By and Lisa Pham Save Short sellers raised their wagers against the bonds and shares of Worldline SA, the French company whose market value slumped €500 million on reports that the firm allegedly covered up fraud by some of its customers, in the days before the stories were published. The amount of bonds maturing in 2030 out on loan — a measure of short interest — rose to almost 78 million on Tuesday, according to data compiled by S&P Global Market Intelligence. That's more than three times the level on June 12. Meanwhile, short interest as measured by the percent of outstanding shares out on loan has risen by more than two percentage points over the past week, according to the data.
Boston Globe
14-05-2025
- Health
- Boston Globe
GSK buys liver drug from Boston Pharmaceuticals for up to $2 billion
Lilly and Novo are betting that their existing GLP-1 blockbusters can help while others investigate different approaches to a condition that shares some of the same root causes as diabetes and obesity: nutrition, lifestyle and inflammation. The new drug, licensed years ago by Novartis AG to closely held Boston Pharmaceuticals, should have benefits beyond any GLP-1 therapy patients are taking, GSK said. Advertisement GSK shares rose less than 1% in London trading. The stock has been roughly flat since the start of the year. The medicine, called efimosfermin, could help livers damaged both by a build-up of fat or from alcohol use, according to GSK. For now it's in development for damage caused by fat — a disease known by the acronym MASH. Mid-stage trial data on efimosfermin showed a once-a-month injected dose rapidly reversed liver fibrosis and stopped it progressing. Obesity Overlap While GSK isn't directly tackling obesity, the deal fits with its investment in inflammatory conditions that often overlap with excess weight. Another drug it has in development for liver disease could potentially be combined with efimosfermin, it said. Advertisement There are more than 30 medicines in clinical trials, according to Bloomberg Intelligence analysts. Lilly's and Novo's obesity and diabetes blockbusters are some of the most advanced. Lilly also entered into a separate licensing deal for the disease with South Korea's OliX Pharmaceuticals Inc. earlier this year. GSK agreed to pay $1.2 billion upfront for efimosfermin, with potential for additional milestone payments totaling $800 million. The new drug is expected to launch in 2029. Boston Pharmaceuticals licensed the medicine from Novartis in 2020, with GSK now on the hook for success-based milestone payments and tiered royalties to the Swiss drugmaker. --With assistance from Lisa Pham.
